{"id":1805,"date":"2023-03-16T14:29:00","date_gmt":"2023-03-16T13:29:00","guid":{"rendered":"https:\/\/niho.sk\/?p=1805"},"modified":"2024-03-30T14:53:20","modified_gmt":"2024-03-30T13:53:20","slug":"18a-liecivo-abemaciklib-liek-verzenios-v-kombinacii-s-tamoxifenom-alebo-inhibitormi-aromatazy-na-adjuvantnu-liecbu-pacientov-s-vcasnym-hr-her2-karcinomom-prsnika-s-pozitivnymi-uzlinami-a-vysokym","status":"publish","type":"post","link":"https:\/\/niho.sk\/en\/18a-liecivo-abemaciklib-liek-verzenios-v-kombinacii-s-tamoxifenom-alebo-inhibitormi-aromatazy-na-adjuvantnu-liecbu-pacientov-s-vcasnym-hr-her2-karcinomom-prsnika-s-pozitivnymi-uzlinami-a-vysokym\/","title":{"rendered":"18A: Lie\u010divo abemaciklib (liek Verzenios) v kombin\u00e1cii s tamoxif\u00e9nom alebo inhib\u00edtormi aromat\u00e1zy na adjuvantn\u00fa lie\u010dbu pacientov s v\u010dasn\u00fdm HR+\/HER2- karcin\u00f3mom prsn\u00edka s pozit\u00edvnymi uzlinami a vysok\u00fdm rizikom recid\u00edvy"},"content":{"rendered":"
    \n
  1. Ak\u00e1 je z\u00e1\u0165a\u017e ochorenia pre pacienta? Ako z\u00e1sadn\u00e9 je ochorenie?<\/strong><\/li>\n<\/ol>\n\n\n\n

    Karcin\u00f3m prsn\u00edka je celosvetovo naj\u010dastej\u0161\u00edm n\u00e1dorov\u00fdm ochoren\u00edm u \u017eien a aj naj\u010dastej\u0161ou pr\u00ed\u010dinou \u00famrtia \u017eien v s\u00favislosti s onkologick\u00fdm ochoren\u00edm. V\u010dasn\u00fd karcin\u00f3m prsn\u00edka sa pova\u017euje za lie\u010dite\u013en\u00fd, av\u0161ak a\u017e 20 % pacientok bude ma\u0165 rekurenciu do 10 rokov od diagn\u00f3zy. Karcin\u00f3m prsn\u00edka sa ozna\u010duje ako v\u010dasn\u00fd, ak sa n\u00e1dor neroz\u0161\u00edril za lymfatick\u00e9 uzliny v podpazu\u0161\u00ed (tie\u017e ako \u0161t\u00e1dium 0-IIA karcin\u00f3mu prsn\u00edka).<\/p>\n\n\n\n

    Karcin\u00f3m prsn\u00edka u \u017eien je naj\u010dastej\u0161ou pr\u00ed\u010dinou \u00famrt\u00ed spojen\u00fdch s rakovinou a vyskytuje sa naj\u010dastej\u0161ie u postmenopauz\u00e1lnych \u017eien vo veku po 50 roku \u017eivota. Karcin\u00f3m prsn\u00edka sa vyskytuje aj u mu\u017eov hoci ve\u013emi zriedkavo, tvor\u00ed pribli\u017ene 1 % v\u0161etk\u00fdch pr\u00edpadov karcin\u00f3mu prsn\u00edka.<\/p>\n\n\n\n

      \n
    1. O ak\u00fd liek ide?<\/strong><\/li>\n<\/ol>\n\n\n\n

      Verzenios je protirakovinov\u00fd liek obsahuj\u00faci \u00fa\u010dinn\u00fa l\u00e1tku abemaciklib. <\/p>\n\n\n\n

      Abemaciklib blokuje \u00fa\u010dinky bielkov\u00edn naz\u00fdvan\u00fdch cykl\u00edndependentn\u00e1 kin\u00e1za 4 a 6. Tieto bielkoviny s\u00fa abnorm\u00e1lne akt\u00edvne v niektor\u00fdch rakovinov\u00fdch bunk\u00e1ch a sp\u00f4sobuj\u00fa ich nekontrolovan\u00fd rast. <\/p>\n\n\n\n

      Blokovanie \u00fa\u010dinku t\u00fdchto bielkov\u00edn m\u00f4\u017ee spoma\u013eova\u0165 rast rakovinov\u00fdch buniek, vies\u0165 ku zmen\u0161eniu n\u00e1doru a oddialeniu postupu ochorenia.<\/p>\n\n\n\n

      Verzenios bol registrovan\u00fd Eur\u00f3pskou liekovou agent\u00farou pre hodnoten\u00fa indik\u00e1ciu d\u0148a 26.09.2018. <\/p>\n\n\n\n

        \n
      1. Ako sa na abemaciklib pozeraj\u00fa odborn\u00edci? <\/strong><\/li>\n<\/ol>\n\n\n\n

        Klinick\u00fd odborn\u00edk a Slovensk\u00e1 onkologick\u00e1 spolo\u010dnos\u0165 by priv\u00edtali kategoriz\u00e1ciu abemaciklibu v indik\u00e1cii adjuvantnej lie\u010dby v\u010dasn\u00e9ho karcin\u00f3mu prsn\u00edka (EBC), \u010d\u00edm by sa zmen\u0161ila frustr\u00e1cia s administrat\u00edvou vybavovania v\u00fdnimiek na lie\u010divo, ktor\u00e9 sa v zahrani\u010d\u00ed pou\u017e\u00edva ako \u0161tandard lie\u010dby a bolo by pr\u00edstupnej\u0161ie v\u00e4\u010d\u0161iemu po\u010dtu pacientov.<\/p>\n\n\n\n

          \n
        1. \u010co hodnotilo NIHO a ak\u00fd je v\u00fdsledok?<\/strong><\/li>\n<\/ol>\n\n\n\n

          Dr\u017eite\u013e registr\u00e1cie (Eli Lilly Nederland B.V. (NLD)) podal \u017eiados\u0165 o zaradenie lieku Verzenios (lie\u010divo abemaciklib) do \u00fahrad z verejn\u00e9ho zdravotn\u00e9ho poistenia pri pou\u017eit\u00ed v kombin\u00e1cii s tamoxif\u00e9nom alebo inhib\u00edtormi aromat\u00e1zy na adjuvantn\u00fa lie\u010dbu pacientov s v\u010dasn\u00fdm HR+\/HER2- karcin\u00f3mom prsn\u00edka s pozit\u00edvnymi uzlinami a vysok\u00fdm rizikom recid\u00edvy. <\/p>\n\n\n\n

          NIHO odpor\u00fa\u010da vyhovie\u0165 \u017eiadosti o kategorizovanie tohto lieku v predmetnej indik\u00e1ci\u00ed, pokia\u013e<\/strong> \u017eiadate\u013e poskytne tak\u00fa z\u013eavu, aby cena sp\u013a\u0148ala krit\u00e9ri\u00e1 n\u00e1kladovej efekt\u00edvnosti. <\/p>\n\n\n\n

          NIHO tie\u017e odpor\u00fa\u010da: <\/p>\n\n\n\n

            \n
          • \u017eiada\u0165 dodato\u010dn\u00fa z\u013eavu vzh\u013eadom na stredn\u00fa mieru neistoty vypl\u00fdvaj\u00facej z nezrelosti d\u00e1t a odhadu pr\u00ednosu v celkovom pre\u017e\u00edvan\u00ed a<\/li>\n\n\n\n
          • zv\u00e1\u017ei\u0165 doplnenie indika\u010dn\u00e9ho obmedzenia o to, aby hradeniu predch\u00e1dzal s\u00fahlas zdravotnej pois\u0165ovne a tie\u017e aby mal pacient dobr\u00fd v\u00fdkonnostn\u00fd stav na ECOG \u0161k\u00e1le.<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"

            NIHO odpor\u00fa\u010da vyhovie\u0165 \u017eiadosti o kategorizovanie tohto lieku v predmetnej indik\u00e1ci\u00ed, pokia\u013e \u017eiadate\u013e poskytne tak\u00fa z\u013eavu, aby cena sp\u013a\u0148ala krit\u00e9ri\u00e1 n\u00e1kladovej efekt\u00edvnosti…<\/p>","protected":false},"author":3,"featured_media":1806,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[11],"tags":[70,71],"class_list":["post-1805","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sumar-hodnotenia","tag-abemaciklib","tag-verzenios"],"_links":{"self":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/posts\/1805","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/comments?post=1805"}],"version-history":[{"count":0,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/posts\/1805\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/media\/1806"}],"wp:attachment":[{"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/media?parent=1805"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/categories?post=1805"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/niho.sk\/en\/wp-json\/wp\/v2\/tags?post=1805"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}